221 related articles for article (PubMed ID: 37227615)
1. Indications and safety of newer IBD treatments in the older patient.
Clement B; De Felice K; Afzali A
Curr Gastroenterol Rep; 2023 Jul; 25(7):160-168. PubMed ID: 37227615
[TBL] [Abstract][Full Text] [Related]
2. Risk of infection in elderly patients with inflammatory bowel disease under biologics: A prospective, multicenter, observational, one-year follow-up comparative study.
Bozon A; Nancey S; Serrero M; Caillo L; Gilletta C; Benezech A; Combes R; Danan G; Akouete S; Pages L; Bourgaux JF; Le Cosquer G; Boivineau L; Meszaros M; Altwegg R
Clin Res Hepatol Gastroenterol; 2023 May; 47(5):102107. PubMed ID: 36906225
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic Drug Monitoring for Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease.
Dutt K; Vasudevan A
Medicina (Kaunas); 2024 Jan; 60(2):. PubMed ID: 38399538
[No Abstract] [Full Text] [Related]
4. Ustekinumab and Vedolizumab Are Equally Safe and Effective in Elderly Crohn's Disease Patients.
Gebeyehu GG; Fiske J; Liu E; Limdi JK; Broglio G; Selinger C; Razsanskaite V; Smith PJ; Flanagan PK; Subramanian S
Dig Dis Sci; 2023 May; 68(5):1983-1994. PubMed ID: 36436155
[TBL] [Abstract][Full Text] [Related]
5. Immunomodulatory Agents for Treatment of Patients with Inflammatory Bowel Disease (Review safety of anti-TNF, Anti-Integrin, Anti IL-12/23, JAK Inhibition, Sphingosine 1-Phosphate Receptor Modulator, Azathioprine / 6-MP and Methotrexate).
Sattler L; Hanauer SB; Malter L
Curr Gastroenterol Rep; 2021 Dec; 23(12):30. PubMed ID: 34913108
[TBL] [Abstract][Full Text] [Related]
6. Comparative Risk of Serious Infections With Biologic Agents and Oral Small Molecules in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis.
Solitano V; Facciorusso A; Jess T; Ma C; Hassan C; Repici A; Jairath V; Armuzzi A; Singh S
Clin Gastroenterol Hepatol; 2023 Apr; 21(4):907-921.e2. PubMed ID: 35944832
[TBL] [Abstract][Full Text] [Related]
7. Ustekinumab and Vedolizumab Are Not Associated With Subsequent Cancer in IBD Patients with Prior Malignancy.
Hong SJ; Zenger C; Pecoriello J; Pang A; Vallely M; Hudesman DP; Chang S; Axelrad JE
Inflamm Bowel Dis; 2022 Dec; 28(12):1826-1832. PubMed ID: 35262671
[TBL] [Abstract][Full Text] [Related]
8. Safety of Biologic Therapy in Older Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis.
Borren NZ; Ananthakrishnan AN
Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1736-1743.e4. PubMed ID: 30616024
[TBL] [Abstract][Full Text] [Related]
9. Dual-Targeted Therapy in Pediatric Inflammatory Bowel Disease: A Comprehensive Review.
Yerushalmy-Feler A; Brauner C; Cohen S
Paediatr Drugs; 2023 Sep; 25(5):489-498. PubMed ID: 37318737
[TBL] [Abstract][Full Text] [Related]
10. Thrombosis in IBD in the Era of JAK Inhibition.
Solitano V; Fiorino G; D'Amico F; Peyrin-Biroulet L; Danese S
Curr Drug Targets; 2021; 22(1):126-136. PubMed ID: 32881668
[TBL] [Abstract][Full Text] [Related]
11. Safety of New Biologics (Vedolizumab and Ustekinumab) and Small Molecules (Tofacitinib) During Pregnancy: A Review.
Gisbert JP; Chaparro M
Drugs; 2020 Jul; 80(11):1085-1100. PubMed ID: 32562207
[TBL] [Abstract][Full Text] [Related]
12. Comorbidity, not patient age, is associated with impaired safety outcomes in vedolizumab- and ustekinumab-treated patients with inflammatory bowel disease-a prospective multicentre cohort study.
Asscher VER; Biemans VBC; Pierik MJ; Dijkstra G; Löwenberg M; van der Marel S; de Boer NKH; Bodelier AGL; Jansen JM; West RL; Haans JJL; van Dop WA; Weersma RK; Hoentjen F; Maljaars PWJ;
Aliment Pharmacol Ther; 2020 Oct; 52(8):1366-1376. PubMed ID: 32901983
[TBL] [Abstract][Full Text] [Related]
13. Prior Immunogenicity to Anti-TNF Biologics Is Not Associated with Increased Anti-drug Antibodies to Vedolizumab or Ustekinumab.
Costable NJ; Borman ZA; Ji J; Dubinsky MC; Ungaro RC
Dig Dis Sci; 2022 Jun; 67(6):2480-2484. PubMed ID: 34021427
[TBL] [Abstract][Full Text] [Related]
14. COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control study.
Alexander JL; Liu Z; Muñoz Sandoval D; Reynolds C; Ibraheim H; Anandabaskaran S; Saifuddin A; Castro Seoane R; Anand N; Nice R; Bewshea C; D'Mello A; Constable L; Jones GR; Balarajah S; Fiorentino F; Sebastian S; Irving PM; Hicks LC; Williams HRT; Kent AJ; Linger R; Parkes M; Kok K; Patel KV; Teare JP; Altmann DM; Goodhand JR; Hart AL; Lees CW; Boyton RJ; Kennedy NA; Ahmad T; Powell N;
Lancet Gastroenterol Hepatol; 2022 Nov; 7(11):1005-1015. PubMed ID: 36088954
[TBL] [Abstract][Full Text] [Related]
15. Risk of Infections With Ustekinumab and Tofacitinib Compared to Tumor Necrosis Factor α Antagonists in Inflammatory Bowel Diseases.
Cheng D; Kochar BD; Cai T; Ananthakrishnan AN
Clin Gastroenterol Hepatol; 2022 Oct; 20(10):2366-2372.e6. PubMed ID: 35066137
[TBL] [Abstract][Full Text] [Related]
16. Comorbidity Influences the Comparative Safety of Biologic Therapy in Older Adults With Inflammatory Bowel Diseases.
Cheng D; Kochar B; Cai T; Ritchie CS; Ananthakrishnan AN
Am J Gastroenterol; 2022 Nov; 117(11):1845-1850. PubMed ID: 35854436
[TBL] [Abstract][Full Text] [Related]
17. No Benefit of Concomitant Immunomodulator Therapy on Efficacy of Biologics That Are Not Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases: A Meta-analysis.
Yzet C; Diouf M; Singh S; Brazier F; Turpin J; Nguyen-Khac E; Meynier J; Fumery M
Clin Gastroenterol Hepatol; 2021 Apr; 19(4):668-679.e8. PubMed ID: 32629124
[TBL] [Abstract][Full Text] [Related]
18. Table: Some drug interactions with drugs for IBD.
Med Lett Drugs Ther; 2023 Jul; 65(1680):e114. PubMed ID: 37418331
[No Abstract] [Full Text] [Related]
19. New drugs for the treatment of IBD during conception, pregnancy, and lactation.
Pugliese D; Privitera G; Gisbert JP; Chaparro M
Dig Liver Dis; 2024 Feb; 56(2):235-241. PubMed ID: 37718225
[TBL] [Abstract][Full Text] [Related]
20. Ustekinumab and vedolizumab for extraintestinal manifestations in inflammatory bowel disease - a retrospective study.
Livne-Margolin M; Ling D; Attia-Konyo S; Abitbol CM; Haj-Natour O; Ungar B; Ben-Horin S; Kopylov U
Dig Liver Dis; 2023 Feb; 55(2):223-229. PubMed ID: 36241535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
